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In Germany, heroin-addicted patients suffering from mental disorders benefited more 
from being prescribed heroin than methadone and did so to almost the same degree as 
other patients, including greater remission in psychiatric symptoms.
Summary Whether heroin addicted patients also suffering from poor mental health 
benefit from being prescribed heroin was the question addressed by the featured report 
from the German heroin prescribing trial. This account draws on an earlier Findings 
analysis of the study, of which the featured report was a sub-study.
The parent study trialled the prescribing of heroin for the treatment of heroin addiction at 
seven German clinics. Over the years 2002 and 2003 it successfully recruited 1015 
patients who were regularly injecting heroin and in poor physical or mental health despite 
being in methadone maintenance treatment, or having been treated for their addiction in 
the past, but not in the last six months.
Patients were randomly allocated to either be prescribed heroin to be taken under 
supervision at the clinics plus oral methadone, or only oral methadone. Cutting across 
this allocation, they were also randomly allocated to two forms of psychosocial support: 
case management conducted along motivational interviewing lines and intended to 
flexibly coordinate an individualised care package from various services; or a more 
standard and directly delivered series of individual counselling and group therapy 
sessions. Which of these support programmes a patient was allocated to made no 
difference to the main outcomes, so reports have focused on the pharmacotherapy 
options.
Earlier reports recorded that compared to methadone, the heroin option retained more 
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patients for a year and enabled more to substantially curb illicit heroin use without 
countervailing increases in cocaine use. More heroin patients also experienced improved 
health. However, the new methadone programme was itself far from ineffective; though 
previous treatment had been unsuccessful, many methadone patients also substantially 
cut their heroin use and experienced improved health.
Main findings
The featured report was based on findings from 626 patients who completed an extended 
assessment of their psychological health. To do this they had to have been retained in 
the study for at least a month. Among these, 485 completed a year of the treatment to 
which they had been allocated.
Initial assessment revealed that at the start of treatment about half were 'dually 
diagnosed' as suffering from a diagnosable psychiatric condition, mainly a disorder of 
mood, neurosis, stress, or psychosomatic conditions. Regardless of whether prescribed 
heroin or methadone, only slightly and non-significantly fewer such patients were 
retained in treatment for a year as patients not suffering mental health problems (in all 
75% v. 80%). Regardless of whether they were dual diagnosis patients, among those 
who were retained, psychological distress and psychiatric symptoms remitted more fully 
among patients prescribed heroin. Like patients in general, given heroin rather than just 
methadone, dual diagnosis patients more often substantially curbed illicit heroin use 
without countervailing increases in cocaine use, and more often experienced substantially 
improved health. However, in these respects the advantage gained by heroin was slightly 
less than among patients not diagnosed with a psychiatric condition.
The authors' conclusions
Among the study's caseload (continuing to regularly inject heroin and in poor physical or 
mental health despite prior or current treatment), as with other patients, patients with 
psychiatric conditions benefited more from heroin prescribing than methadone-only 
programmes in terms of improved health and reduced illicit drug use. However, these 
benefits were slightly less marked than among other patients, perhaps partly because 
anxiety or depressive disorders respond to methadone's sedative effects. However, the 
study excluded patients whose mental disorders were so severe that they jeopardised 
participation in the trial, accounting for the unusually low number suffering from 
schizophrenia-type disorders. The same limitation applies to patients with personality 
disorders.
The implication is that psychiatric comorbidity of the kind included in the trial need not be 
a reason to exclude patients from heroin-based treatment and that, more so than 
methadone, such treatment can help resolve their psychiatric and substance use 
problems. The structure and clinical contact imposed by having to visit the clinic several 
times a day for supervised heroin consumption may have been one reason why dual 
diagnosis patients responded well to this treatment.
This draft entry is currently subject to consultation and correction by study authors.
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